Menu
GeneBe

rs572846

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_003793.4(CTSF):c.1401T>C(p.Arg467=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.544 in 1,613,410 control chromosomes in the GnomAD database, including 244,359 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.61 ( 29741 hom., cov: 33)
Exomes 𝑓: 0.54 ( 214618 hom. )

Consequence

CTSF
NM_003793.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: -1.01
Variant links:
Genes affected
CTSF (HGNC:2531): (cathepsin F) Cathepsins are papain family cysteine proteinases that represent a major component of the lysosomal proteolytic system. Cathepsins generally contain a signal sequence, followed by a propeptide and then a catalytically active mature region. The very long (251 amino acid residues) proregion of the cathepsin F precursor contains a C-terminal domain similar to the pro-segment of cathepsin L-like enzymes, a 50-residue flexible linker peptide, and an N-terminal domain predicted to adopt a cystatin-like fold. The cathepsin F proregion is unique within the papain family cysteine proteases in that it contains this additional N-terminal segment predicted to share structural similarities with cysteine protease inhibitors of the cystatin superfamily. This cystatin-like domain contains some of the elements known to be important for inhibitory activity. CTSF encodes a predicted protein of 484 amino acids which contains a 19 residue signal peptide. Cathepsin F contains five potential N-glycosylation sites, and it may be targeted to the endosomal/lysosomal compartment via the mannose 6-phosphate receptor pathway. The cathepsin F gene is ubiquitously expressed, and it maps to chromosome 11q13, close to the gene encoding cathepsin W. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BP6
Variant 11-66563987-A-G is Benign according to our data. Variant chr11-66563987-A-G is described in ClinVar as [Benign]. Clinvar id is 259168.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-66563987-A-G is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-1.01 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.817 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CTSFNM_003793.4 linkuse as main transcriptc.1401T>C p.Arg467= synonymous_variant 13/13 ENST00000310325.10
CTSFXM_011545328.3 linkuse as main transcriptc.1221T>C p.Arg407= synonymous_variant 13/13

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CTSFENST00000310325.10 linkuse as main transcriptc.1401T>C p.Arg467= synonymous_variant 13/131 NM_003793.4 P3

Frequencies

GnomAD3 genomes
AF:
0.609
AC:
92535
AN:
151964
Hom.:
29684
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.824
Gnomad AMI
AF:
0.430
Gnomad AMR
AF:
0.446
Gnomad ASJ
AF:
0.528
Gnomad EAS
AF:
0.531
Gnomad SAS
AF:
0.395
Gnomad FIN
AF:
0.634
Gnomad MID
AF:
0.544
Gnomad NFE
AF:
0.539
Gnomad OTH
AF:
0.579
GnomAD3 exomes
AF:
0.521
AC:
130253
AN:
250108
Hom.:
35965
AF XY:
0.518
AC XY:
70156
AN XY:
135424
show subpopulations
Gnomad AFR exome
AF:
0.826
Gnomad AMR exome
AF:
0.327
Gnomad ASJ exome
AF:
0.544
Gnomad EAS exome
AF:
0.547
Gnomad SAS exome
AF:
0.396
Gnomad FIN exome
AF:
0.634
Gnomad NFE exome
AF:
0.543
Gnomad OTH exome
AF:
0.516
GnomAD4 exome
AF:
0.537
AC:
784612
AN:
1461328
Hom.:
214618
Cov.:
81
AF XY:
0.534
AC XY:
388057
AN XY:
726968
show subpopulations
Gnomad4 AFR exome
AF:
0.839
Gnomad4 AMR exome
AF:
0.342
Gnomad4 ASJ exome
AF:
0.537
Gnomad4 EAS exome
AF:
0.511
Gnomad4 SAS exome
AF:
0.402
Gnomad4 FIN exome
AF:
0.631
Gnomad4 NFE exome
AF:
0.542
Gnomad4 OTH exome
AF:
0.542
GnomAD4 genome
AF:
0.609
AC:
92641
AN:
152082
Hom.:
29741
Cov.:
33
AF XY:
0.605
AC XY:
44967
AN XY:
74340
show subpopulations
Gnomad4 AFR
AF:
0.825
Gnomad4 AMR
AF:
0.446
Gnomad4 ASJ
AF:
0.528
Gnomad4 EAS
AF:
0.531
Gnomad4 SAS
AF:
0.396
Gnomad4 FIN
AF:
0.634
Gnomad4 NFE
AF:
0.539
Gnomad4 OTH
AF:
0.575
Alfa
AF:
0.556
Hom.:
29139
Bravo
AF:
0.607
Asia WGS
AF:
0.491
AC:
1709
AN:
3478
EpiCase
AF:
0.541
EpiControl
AF:
0.540

ClinVar

Significance: Benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Neuronal ceroid lipofuscinosis 13 Benign:4
Benign, criteria provided, single submitterclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical CenterSep 21, 2015- -
Benign, criteria provided, single submitterclinical testingInvitaeJan 30, 2024- -
Benign, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, Amsterdam University Medical CenterApr 22, 2016- -
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabJul 30, 2021- -
not provided Benign:3
Benign, criteria provided, single submitterclinical testingAthena DiagnosticsApr 20, 2017- -
Benign, criteria provided, single submitterclinical testingGeneDxJun 13, 2018This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, no assertion criteria providedclinical testingMayo Clinic Laboratories, Mayo ClinicOct 22, 2015- -
not specified Benign:2
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact Sciences-- -
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Dec 23, 2015- -
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitterclinical testingAmbry GeneticsJan 08, 2016This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.82
Cadd
Benign
1.9
Dann
Benign
0.59

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs572846; hg19: chr11-66331458; COSMIC: COSV59747923; COSMIC: COSV59747923; API